2/3
09:14 am
prld
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor [Yahoo! Finance]
High
Report
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor [Yahoo! Finance]
2/3
09:00 am
prld
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Low
Report
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
1/18
01:00 am
prld
Prelude Therapeutics (NASDAQ:PRLD) was downgraded by analysts at
Wall St
Low
Report
Prelude Therapeutics (NASDAQ:PRLD) was downgraded by analysts at
Wall St
1/10
01:07 am
prld
Prelude Therapeutics (NASDAQ:PRLD) was upgraded by analysts at
Wall Stre
High
Report
Prelude Therapeutics (NASDAQ:PRLD) was upgraded by analysts at
Wall Stre
12/29
06:48 am
prld
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability [Yahoo! Finance]
High
Report
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability [Yahoo! Finance]
12/6
11:00 am
prld
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Neutral
Report
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs